subject: Apis New Round Of Market Growth Affected By Three Trends [print this page] 2007, the global pharmaceutical market will maintain a moderate growth rate. According to the latest research, in 2007, global pharmaceutical sales are expected to grow by 5% to 6%, reaching 665 000 000 000 ~ 685 billion U.S. dollars, down from 6% in 2006 to 7% growth rate. However, there are three areas in which performance will be noticeable: First, the demand for biotech drugs is expected to grow strongly, growth rate will reach 13% ~ 14%; Second, generics growth rate will reach 13% ~ 14%; third specialty pharmaceutical growth rate will reach 10% to 11%.
These three kinds of trends will further affect the development of bulk drug market is expected to generic API global commodity demand growth can be "strong" word to describe.
The main competition between India and China will be the traditional powers Italy and Spain APIs competition, improve raw materials in the global generic drug market share; in the enterprise itself has always been based mainly on the biological medicine API production is expected to continue to stay ahead of the United States.
Generic generic API to promote a fast track
As Norvasc, to the Secretary of risperidone and other drugs of concern the patent will expire one after another, the global generics market will usher in strong growth. By 2015, sales of 160 billion U.S. dollars of drugs will lose patent protection, generic drug sales will increase. 2008,2011 expected to become generic in particularly strong growth year. In the next 5 years, 2005 sales of approximately 800 million worth of drugs will face generic competition, while 2011 to 2015, another 77 billion U.S. dollars of drugs will be the impact of generics.
Global generics growth caused by an obvious influence is the generic API market demand amplification. Chemical Pharmaceutical generic drugs, according to Association (ChemicalPharmaceuticalGenericAssociation, CPA) statistics show that in 2005, the global bulk drug market for human use (including bulk drugs and bulk drugs used in the production of high-level intermediate) reached 76 billion U.S. dollars; of which, about 59% (about 45 billion U.S. dollars) is manufactured by the pharmaceutical companies themselves, and the remaining 41% (about 31 billion U.S. dollars) is produced by a third party as a commodity sold to pharmaceutical companies.
In the commodities markets bulk drugs, bulk drugs about 70% to 75% (about 220 billion to 23 billion U.S. dollars), accounting for the remaining high-level intermediate between 25% and 30% (80 billion to 9 billion U.S. dollars). In 2005, all goods raw materials (including bulk drugs and high-intermediate) market, generic drugs accounted for 43.5% of raw materials (135 million), brand, or 56.5% accounted for innovative API (175 million).
According to CPA is expected in the next five years, the world's entire raw materials (including brand or generic drugs and innovative raw materials API) demand will grow 8.2% annually. By 2010, commodity bulk drugs market is expected to reach 46 billion U.S. dollars, of which growth generic bulk drugs over branded drugs, or innovative raw material medicine. The next 5 years, generic API is expected to grow an average annual growth rate of 10.9%, to 2010, will reach 22.7 billion U.S. dollars; the brand or innovation API API is expected to grow 5.9% average annual growth rate to 2010, will reach 23.3 billion. Generic drugs and brand of raw materials or innovative growth rate of different API will change the composition of bulk drugs market by 2010, generic drugs and brand of raw materials or bulk drugs will be equally shared innovation, respectively, accounted for 49.4%, 50.6%.
